MDH-7 (2,3,9-tri-O-acetyl-5,6-dideoxy-1,10-di-[N4′-pentoxycarbonyl-5′-fluoro cytosine]-4-ulose 1,4: 7,10-difuranose-4,8-pyranose) is a novel anti-tumor drug candidate. To study the pharmacokinetic interaction between MDH-7 and 5-fluorouracil (5-FU), a sensitive and rapid liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed to simultaneously determine the concentrations of MDH-7 and 5-fluorouracil (5-FU) in rat plasma. Plasma samples were prepared by simple liquid-liquid extraction with ethyl acetate. Chromatographic separation was performed on a Waters XBridge™ C18 column (5 μm, 2.1 mm × 150 mm) with the mobile phase of methanol and H₂O (80:20, v/v). The ESI positive and negative ion switch was operated in the multiple reactions monitoring (MRM) mode. The calibration curves showed good linearity (r² > 0.99) over the ranges of 50–8000 ng/mL for MDH-7 and 10–2000 ng/mL for 5-FU, respectively. The lower limit of quantitations (LLOQs) was 50 ng/mL (MDH-7) and 10 ng/mL (5-FU) with relative standard deviation (RSD) < 13.0%. The proposed method was successfully applied to simultaneous assessment of pharmacokinetic drug-drug interaction between MDH-7 and 5-FU in rats.

MDH-7（2,3,9-三-O-乙酰基-5,6-二脱氧-1,10-二-[N4'-戊氧羰基-5'-氟胞嘧啶] -4-ulose 1,4：7， 10-difuranose-4,8-​​pyranose）是一种新型的抗肿瘤药物候选物。为了研究MDH-7和5-氟尿嘧啶（5-FU）之间的药代动力学相互作用，开发了一种灵敏而快速的液相色谱-串联质谱（LC-MS / MS）方法来同时测定MDH-7和5的浓度-大鼠血浆中的氟尿嘧啶（5-FU）。通过用乙酸乙酯进行简单的液-液萃取来制备血浆样品。色谱分离是在Waters XBridge™C18色谱柱（5μm，2.1 mm×150 mm）上进行的，流动相为甲醇和H _2。O（80:20，v / v）。ESI正负离子开关在多反应监测（MRM）模式下运行。校准曲线 在MDH-7的50–8000 ng / mL和5-FU的10–2000 ng / mL的范围内分别显示出良好的线性（r ² > 0.99）。定量下限（LLOQs）为50 ng / mL（MDH-7）和10 ng / mL（5-FU），相对标准偏差（RSD）<13.0％。所提出的方法已成功地应用于同时评估MDH-7和5-FU在大鼠体内的药代动力学药物相互作用。